8-K: Stereotaxis Reports Q1 2024 Results and Announces Acquisition of Access Point Technologies

Stereotaxis announced its first quarter 2024 financial results, showing revenue growth and an increase in system backlog, alongside the acquisition of Access Point Technologies to expand its catheter capabilities.

Summary

• Stereotaxis reported a 5% increase in revenue for the first quarter of 2024, reaching $6.9 million compared to $6.5 million in the same period last year.
• System revenue increased to $2.6 million, while recurring revenue was $4.3 million.
• The company's gross margin was 58%, with recurring revenue gross margin at 76% and system gross margin at 27%.
• Operating loss for the quarter was $4.7 million, and net loss was $4.5 million, both improvements compared to the previous year.
• Adjusted operating loss and adjusted net loss, excluding non-cash stock compensation, were $2.2 million and $1.9 million, respectively.
• Stereotaxis had $18.2 million in cash and cash equivalents with no debt as of March 31, 2024.
• The company maintains its expectation of double-digit revenue growth for the full year 2024.
• Stereotaxis also announced the acquisition of Access Point Technologies (APT), a developer of electrophysiology catheters, for an upfront payment and contingent payments in Stereotaxis common stock.
• APT is expected to contribute approximately $5 million in annual revenue during the first year post-acquisition.
• The acquisition is expected to close in the third quarter of 2024.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the revenue growth, strategic acquisition, and progress on new product development. However, the company is still operating at a loss, which tempers the overall sentiment.

Positives

• Revenue increased by 5% year-over-year in the first quarter of 2024.
• System revenue saw a significant increase compared to the same quarter last year.
• The company's adjusted operating and net losses improved compared to the previous year.
• Stereotaxis has a strong cash balance of $18.2 million and no debt.
• The acquisition of APT is expected to provide valuable commercial synergies and strengthen the company strategically.
• The company is making progress on regulatory submissions for new products.
• Stereotaxis maintains its expectation of double-digit revenue growth for the full year 2024.

Negatives

• The company reported an operating loss of $4.7 million and a net loss of $4.5 million for the first quarter of 2024.
• Negative free cash flow for the first quarter was $2.3 million.
• First quarter cash utilization is typically higher than subsequent quarters.

Risks

• The company's ability to manage expenses at sustainable levels is a risk.
• Acceptance of the company's products in the marketplace is not guaranteed.
• Global economic conditions could affect customers' ability and willingness to purchase the technology.
• Competitive factors could impact the company's performance.
• Changes in healthcare policy could affect the company.
• The company is dependent on third-party vendors.
• The timing of regulatory approvals is uncertain.
• The integration of APT may present challenges.
• There is no guarantee that the company will recognize revenue related to its purchase orders and other commitments.

Future Outlook

Stereotaxis maintains its expectation of double-digit revenue growth for the full year 2024, driven by system backlog and new orders, and anticipates a lower rate of cash utilization, even with the APT acquisition. The company believes it can reach profitability without additional financing.

Management Comments

• David Fischel, Chairman and CEO, stated that Stereotaxis is driving continued commercial, technological, and strategic progress.
• David Fischel also mentioned that the acquisition of APT provides valuable commercial synergies and strengthens the company strategically.
• Steve Berhow, President of Access Point Technologies, expressed excitement about joining Stereotaxis and contributing their expertise in EP catheters.

Industry Context

This announcement reflects a trend in the medical device industry towards consolidation and strategic acquisitions to expand product portfolios and market reach. The acquisition of APT allows Stereotaxis to integrate catheter development and manufacturing capabilities, which is a key area of growth in the electrophysiology market.

Comparison to Industry Standards

• The 5% revenue growth is modest compared to some high-growth medical device companies, but it is positive given the company's focus on robotics and specialized markets.
• The gross margin of 58% is within the typical range for medical device companies, but the system gross margin of 27% is lower than the recurring revenue gross margin of 76%, indicating a potential area for improvement.
• Companies like Intuitive Surgical (ISRG) and Medtronic (MDT) have higher revenue and profitability, but they operate in larger markets. Stereotaxis is focused on a niche market within endovascular surgery.
• The acquisition of APT is similar to other strategic acquisitions in the medical device space, where companies acquire smaller players to gain access to new technologies and markets.

Stakeholder Impact

• Shareholders will benefit from the potential revenue growth and strategic advantages of the APT acquisition.
• Employees may experience changes due to the integration of APT.
• Customers will have access to a broader range of products and services.
• Suppliers may see increased demand due to the company's growth.
• Creditors are likely to view the company's financial position as stable.

Next Steps

• Stereotaxis will continue to advance its technology and strategy.
• The company will focus on integrating APT into its operations.
• Regulatory submissions for the smaller robot are expected in the second quarter.
• Commercial launches of new products are expected later this year.
• The acquisition of APT is expected to close in the third quarter of 2024.

Key Dates

Keywords

Stereotaxis, Surgical Robotics, Electrophysiology, Catheters, Acquisition, Financial Results, Revenue Growth, Medical Devices, Robotics, Healthcare